Rituximab combination therapy in relapsing multiple sclerosis

Therapeutic Advances in Neurological Disorders

Volumn 5, Issue 6, 2012, Pages 311-319

  Cross, Anne H ^a   Klein, Robyn S ^b   Piccio, Laura ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

B cells; chemokines; CXCL13; gadolinium enhanced magnetic resonance imaging; multiple sclerosis; rituximab; T cells

Indexed keywords

B CELL ACTIVATING FACTOR MONOCLONAL ANTIBODY; B7 ANTIGEN; BETA1A INTERFERON; CD20 ANTIGEN; CD86 ANTIGEN; CXCL13 CHEMOKINE; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCLONAL ANTIBODY; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN PROTEIN; PLACEBO; PREDNISONE; PROTEIN ANTIBODY; RITUXIMAB; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; B LYMPHOCYTE; BRAIN DAMAGE; BRONCHITIS; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID CYTOLOGY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DIARRHEA; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEVER; FLUSHING; HODGKIN DISEASE; HUMAN; HUMORAL IMMUNE DEFICIENCY; INFUSION RELATED REACTION; LYMPHOCYTE COUNT; MICROSCOPIC POLYANGIITIS; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MUSCLE SPASM; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; RECURRENT DISEASE; RELAPSE; REVIEW; SIDE EFFECT; T LYMPHOCYTE; TARGET CELL; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 84868246228     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285612461165     Document Type: Article

References (30)

1. Alt C. Laschinger M. Engelhardt B. (2002) Functional expression of the lymphoid chemokines CCL 19 (ELC) and CCL 21 (SLC) at the blood–brain barrier suggests their involvement in G-protein-dependent lymphocyte recruitment into the central nervous system during experimental autoimmune encephalomyelitis. Eur J Immunol 32: 2133–2144.
2. Avasarala J. Cross A. Trotter J. (2001) Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch Neurol 58: 2044–2045.
3. Baranzini S. Jeong M. Butunoi C. Murray R. Bernard C. Oksenberg J. (1999) B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 163: 5133–5144.
4. Bar-Or A. Calabresi P. Arnold D. Markowitz C. Shafer S. Kasper L. et al. (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63: 395–400.
5. Buonamici S. Trimarchi T. Ruocco M. Reavie L. Cathelin S. Mar B. et al. (2009) CCR 7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 459: 1000–1004.
6. Cheson B. (2010) Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 28: 3525–3530.
7. Colombo M. Dono M. Gazzola P. Roncella S. Valetto A. Chiorazzi N. et al. (2000) Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol 164: 2782–2789.
8. Cross A. Stark J. Lauber J. Ramsbottom M. Lyons J. (2006) Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 180: 63–70.
9. Engelhardt B. (2006) Regulation of immune cell entry into the central nervous system. Results Probl Cell Differ 43: 259–280.
10. Hartung H. Kieseier B. (2010) Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord 3: 205–216.
11. Hauser S. Waubant E. Arnold D. Vollmer T. Antel J. Fox R. et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676–688.
12. Hawker K. O'Connor P. Freedman M. Calabresi P. Antel J. Simon J. et al. (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66: 460–471.
13. Kappos L. Li D. Calabresi P. O'Connor P. Bar-Or A. Barkhof F. et al. (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378: 1779–1787.
14. Khademi M. Kockum I. Andersson M. Iacobaeus E. Brundin L. Sellebjerg F. et al. (2011) Cerebrospinal fluid CXCL 13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler 17: 335–343.
15. Kowarik M. Cepok S. Sellner J. Grummel V. Weber M. Korn T. et al. (2012) CXCL 13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation 9: 93.
16. Krumbholz M. Theil D. Cepok S. Hemmer B. Kivisakk P. Ransohoff R. et al. (2006) Chemokines in multiple sclerosis: CXCL 12 and CXCL 13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 129: 200–211.
17. Krumbholz M. Theil D. Steinmeyer F. Cepok S. Hemmer B. Hofbauer M. et al. (2007) CCL 19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. J Neuroimmunol 190: 72–79.
18. Lalor S. Segal B. (2010) Lymphoid chemokines in the CNS. J Neuroimmunol 224: 56–61.
19. Langford C. (2012) Update on the treatment of granulomatosis with polyangiitis (Wegener's). Curr Treat Options Cardiovasc Med 14: 164–176.
20. Lucchinetti C. Bruck W. Rodriguez M. Lassmann H. (1996) Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 6: 259–274.
21. Magliozzi R. Howell O. Vora A. Serafini B. Nicholas R. Puopolo M. et al. (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130: 1089–1104.
22. Naismith R. Piccio L. Lyons J. Lauber J. Tutlam N. Parks B. et al. (2010) Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 74: 1860–1867.
23. Olsson J. Link H. (1973) Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: exacerbations and remissions. Arch Neurol 28: 392–399.
24. Piccio L. Naismith R. Trinkaus K. Klein R. Parks B. Lyons J. et al. (2010) Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 67: 707–714.
25. Prineas J. Wright R. (1978) Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 38: 409–421.
26. Qin Y. Duquette P. Zhang Y. Talbot P. Poole R. Antel J. (1998) Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 102: 1045–1050.
27. Roxburgh R. Seaman S. Masterman T. Hensiek A. Sawcer S. Vukusic S. et al. (2005) Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 64: 1144–1151.
28. Serafini B. Rosicarelli B. Magliozzi R. Stigliano E. Aloisi F. (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14: 164–174.
29. Trotter J. Rust R. (1989) Human cerebrospinal fluid immunology. In: Ed. Brumbach R. Herdon R. (eds), Cerebrospinal Fluid. Amsterdam: Martinus Nyhoff, pp. 179–226.
30. Zeman A. Kidd D. McLean B. Kelly M. Francis D. Miller D. et al. (1996) A study of oligoclonal band negative multiple sclerosis. J Neurol Neurosurg Psychiatry 60: 27–30.